Related Experiment Video
Updated: Jun 12, 2026

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis
Published on: June 27, 2020
Oncogenic partnerships: EWS-FLI1 protein interactions initiate key pathways of Ewing's sarcoma
Hayriye V Erkizan1, Vladimir N Uversky, Jeffrey A Toretsky
1Department of Oncology and Pediatrics, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.
Abstract:
Targeted therapy for cancer, which is specifically directed toward the cancer without any potential for effects outside of controlling the tumor, is a gold standard for treatment. Ewing's sarcoma contains the potential target EWS-FLI1, as a result of a pathognomonic chromosomal translocation. The EWS-FLI1 fusion protein includes the EWS domain, a potent transcriptional activator alongside the highly conserved FLI1 ets DNA-binding domain. Because of the combination of these domains, the EWS-FLI1 fusion protein acts as an aberrant transcription factor whose expression results in cellular transformation. EWS-FLI1 functions by binding to normal cellular protein partners in transcription and splicing, similar to how a virus would corrupt normal cellular machinery for virion production. Therefore, understanding the protein-protein interactions of EWS-FLI1 and the pathways that are regulated by these partnerships will inform both oncogenesis and therapeutics. This review describes the known protein partners and transcriptional targets of EWS-FLI1, while proposing strategies for exploiting these partnerships with targeted therapy.
Insights
Targeted cancer therapy is a gold standard. This review explores the EWS-FLI1 fusion protein in Ewing's sarcoma, detailing its interactions and therapeutic targets.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Targeted cancer therapy aims to attack tumors with minimal harm to healthy cells.
- Ewing's sarcoma is characterized by the EWS-FLI1 fusion protein, arising from a specific chromosomal translocation.
- The EWS-FLI1 protein combines a transcriptional activator (EWS) with a DNA-binding domain (FLI1), leading to cellular transformation.
Purpose of the Study:
- To review known protein partners and transcriptional targets of the EWS-FLI1 fusion protein.
- To propose strategies for developing targeted therapies against Ewing's sarcoma by exploiting EWS-FLI1 interactions.
Main Methods:
- Literature review of studies on EWS-FLI1 protein-protein interactions.
- Analysis of pathways regulated by EWS-FLI1 partnerships.
- Identification of potential therapeutic targets based on these interactions.
Main Results:
- The EWS-FLI1 fusion protein acts as an aberrant transcription factor by interacting with normal cellular proteins.
- These interactions disrupt normal cellular machinery, contributing to oncogenesis.
- Specific protein partners and regulated pathways have been identified.
Conclusions:
- Understanding EWS-FLI1 protein interactions is crucial for comprehending Ewing's sarcoma development.
- Targeting these specific interactions offers a promising strategy for novel therapeutic interventions.
- Further research into EWS-FLI1 partnerships can guide the development of effective Ewing's sarcoma treatments.
Related Concept Videos
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Non-Canonical Wnt Signaling Pathways
Non-Canonical Wnt Signaling Pathways
Mitogens and the Cell Cycle
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

